IMRX vs. AADI, CLNN, NBRV, RMTI, BOLT, NXTC, RVPH, OCUP, HCWB, and BLRX
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Aadi Bioscience (AADI), Clene (CLNN), Nabriva Therapeutics (NBRV), Rockwell Medical (RMTI), Bolt Biotherapeutics (BOLT), NextCure (NXTC), Reviva Pharmaceuticals (RVPH), Ocuphire Pharma (OCUP), HCW Biologics (HCWB), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience (NASDAQ:AADI) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.
Immuneering has lower revenue, but higher earnings than Aadi Bioscience. Immuneering is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Aadi Bioscience has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500.
52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 35.8% of Aadi Bioscience shares are held by insiders. Comparatively, 25.0% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Aadi Bioscience had 8 more articles in the media than Immuneering. MarketBeat recorded 11 mentions for Aadi Bioscience and 3 mentions for Immuneering. Immuneering's average media sentiment score of 0.03 beat Aadi Bioscience's score of -0.17 indicating that Aadi Bioscience is being referred to more favorably in the media.
Aadi Bioscience presently has a consensus price target of $20.50, indicating a potential upside of 973.30%. Immuneering has a consensus price target of $13.50, indicating a potential upside of 818.37%. Given Immuneering's higher possible upside, research analysts clearly believe Aadi Bioscience is more favorable than Immuneering.
Immuneering has a net margin of 0.00% compared to Immuneering's net margin of -288.72%. Aadi Bioscience's return on equity of -55.79% beat Immuneering's return on equity.
Immuneering received 13 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 61.54% of users gave Immuneering an outperform vote while only 47.83% of users gave Aadi Bioscience an outperform vote.
Summary
Immuneering beats Aadi Bioscience on 10 of the 17 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
